Abstract：Objective: To explore the impact of bevacizumab combined with capecitabine maintenance on the prognosis of patients with advanced colorectal cancer. Methods: Clinical data of 101 patients with advanced colorectal cancer treated in our hospital from January 2017 to January 2019 were collected. All patients received first-line chemotherapy based on 5-fluorouracil and capecitabine, combined with bevacizumab and mFOLFOX6 or XELOX regimen. Among them, 42 patients received capecitabine monotherapy maintenance treatment after first-line chemotherapy (control group), and 59 patients received bevacizumab combined with capecitabine maintenance treatment (observation group). Both groups were treated until disease progression or intolerable toxic reactions. The maintenance treatment time, disease control time, Karnofsky Performance Status (KPS), Eastern Cooperative Oncology Group performance status (ZPS), serum tumor marker levels, adverse reactions, and long-term prognosis were compared between the two groups. Results: The maintenance treatment time and disease control time in the observation group were both longer than those in the control group (P<0.05). Both groups showed an increase in KPS and a decrease in ZPS after treatment, and the change in the observation group was greater than that in the control group (P<0.05). The serum levels of CEA, CA199, and CA724 in both groups decreased compared to before treatment, and the change in the observation group was greater than that in the control group (P<0.05). There was no statistically significant difference in the occurrence of adverse reactions between the two groups (P>0.05). The overall survival rate in the observation group was higher than that in the control group (P<0.05). Conclusion: Bevacizumab combined with capecitabine maintenance treatment after first-line treatment for advanced colorectal cancer is safe and effective, prolonging survival time with mild adverse reactions.
胡丽霞, 汪超. 贝伐珠单抗联合卡培他滨维持对晚期结肠癌患者预后的影响[J]. 河北医学, 2024, 30(1): 158-163.
HU Lixia, WANG Chao. The Impact of Bevacizumab Combined with Capecitabine Maintenance on the Prognosis of Patients with Advanced Colorectal Cancer. HeBei Med, 2024, 30(1): 158-163.
[1] 卢元丽,张志国,张 颖,等.贝伐珠单抗联合XELOX化疗方案治疗老年晚期结直肠癌肝转移患者的临床观察[J].中西医结合肝病杂志,2021,31(9):806-812. [2] 刘传亮.腹腔热灌注化疗对结肠癌术后患者CEACA19-9及临床疗效的影响[J].河北医学,2016,22(9):1472-1474. [3] Cavaletti G,Frigeni B,Lanzani F,et al.The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity:comparison with the national cancer institute-common toxicity scale[J].Peripher Nerv Syst,2010,12(3):210-215. [4] 席向艳,王有广,张念杰,等.贝伐珠单抗联合FOLFOX6治疗直肠癌的效果及对患者免疫功能的影响[J].结直肠肛门外科,2021,27(2):7-8. [5] 李剑萍,高学仁,张晓艳,等.卡培他滨联合贝伐珠单抗或卡培他滨单药在晚期结直肠癌维持治疗中的疗效与安全性[J].昆明医科大学学报,2021,42(9):119-126. [6] 邓文静,余更生,刘 爱,等.贝伐珠单抗联合mFOLFOX6治疗转移性结直肠癌的临床疗效及左右半结肠癌的疗效差异[J].现代肿瘤医学,2020,28(5):94-98. [7] Elshenawy M A,Badran A,Aljubran A,et al.Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer[J].World J Surg Oncol,2020,18(1):163-165. [8] Cutsem E V,Danielewicz I,Saunders M P,et al.Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy:the randomized TASCO1 study[J].Ann Oncol,2020,31(9):1160-1168. [9] Bang Y H,Kim J E,Ji S L,et al.Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan,oxaliplatin,and fluoropyrimidines[J].Sci Rep,2021,11(1):227-229. [10] 王婷,胡玉海,白琳,等.贝伐珠单抗联合伊立替康和卡培他滨治疗大肠癌的疗效分析[J].现代消化及介入诊疗,2022,27(4):508-512.
2024, Vol. 30 
冀公网安备13080202000677号